Protara Therapeutics, Inc. — Director's Dealing 2020

Jul 27, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2020-07-23

Reporting Person: Flannelly Barry P (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-23	Stock Option (Right to Buy)	$26.70	A	18000	Acquired	2030-07-22	Common Stock (18000)	Direct
2020-07-23	Stock Option (Right to Buy)	$26.70	A	8250	Acquired	2030-07-22	Common Stock (8250)	Direct

Footnotes

F1: The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.

F2: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.